Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Focus**: Precision neuroscience, specifically targeting receptor-associated proteins related to AMPA receptors, which are crucial in the treatment of epilepsy [2][4] Key Points and Arguments Unique Mechanism of Action - Rapport Therapeutics is developing RAP-219, which targets TARP gamma 8, an auxiliary protein associated with AMPA receptors, selectively expressed in brain regions critical for focal-onset seizures [3][4] - This selectivity allows for a higher therapeutic index compared to traditional anti-seizure medications, which often have low therapeutic indices and significant side effects [4][10] Clinical Data and Efficacy - The company reported a **72% reduction** in long episodes of electrographic seizures and a **78% median reduction** in clinical seizures during their proof of concept study [13] - A **24% seizure freedom rate** was observed from day 1 to day 56 in the trial [14] - The innovative use of the RNS System for continuous monitoring of electrographic activity allowed for a more efficient study design, reducing the required sample size to 30 patients [16][12] Tolerability Profile - RAP-219 demonstrated a favorable tolerability profile with a **10% discontinuation rate**, which is low for focal epilepsy trials [30] - Common adverse events included dizziness and headache, typical of anti-seizure medications, but were generally mild to moderate [30] Phase 3 Study Plans - Two parallel Phase 3 studies are set to begin in Q2 2026, exploring different dosing strategies (0.25 mg and 0.75 mg in one study, 0.75 mg and 1.25 mg in another) [41] - The studies aim to confirm the efficacy seen in Phase 2 and will include a titration schema over 7-9 days [42] Strategic Partnerships and Market Position - A partnership with Tenacia in China was established, providing a **$20 million upfront payment** and potential for **$308 million in biobucks** and royalties, which will support development in the region [53] - The partnership allows for patient recruitment in China, which has historically been inaccessible for such trials [52] Future Indications and Pipeline - The company plans to expand RAP-219's indications to include primary generalized tonic-clonic seizures and is also exploring its use in bipolar mania, with data expected in 2027 [111][112] - The long-acting injectable (LAI) formulation of RAP-219 is in development, with potential human PK results expected in 2027, which could transform treatment options for epilepsy patients [93][94] Financial Outlook - Rapport Therapeutics has sufficient cash runway into the second half of 2029, allowing for the completion of ongoing studies and the initiation of new trials [121] Additional Important Insights - The company believes that the unique mechanism and efficacy of RAP-219 could position it as a best-in-class therapy for focal-onset seizures [81][88] - The potential for a long-acting injectable formulation could address significant patient needs and extend the revenue durability of the product [96][100] This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Rapport Therapeutics in the epilepsy treatment landscape and its strategic plans for future growth and development.

Summary of NeuroPace Conference Call Company Overview - **Company**: NeuroPace - **Industry**: MedTech, specifically focused on neuromodulation for epilepsy treatment Key Points and Arguments Commercial Momentum and Growth Drivers - NeuroPace has experienced significant growth in its core RNS (Responsive Neurostimulation) business, particularly in focal drug-resistant epilepsy, driven by: 1. **Increased Adoption and Utilization**: Focus on comprehensive epilepsy centers has led to more prescriptions and higher utilization rates [5][6] 2. **Referral Management Improvements**: Investments in identifying and managing patient referrals have streamlined the diagnostic process [6] 3. **Commercial Execution**: Strengthened sales leadership and ongoing investments in the commercial team have contributed to growth [6] Market Position and Technology Differentiation - NeuroPace's RNS technology is unique as it is the only closed-loop neuromodulation device, allowing for real-time monitoring and tailored therapy for patients [7][10] - The company is focused on expanding clinical indications and developing a robust product pipeline to further differentiate its technology [10] 2026 Financial Outlook - Guidance for 2026 is projected at $98 million to $100 million, with potential upside driven by: - Increased productivity and focus of the sales force [12] - Introduction of new products like SeizureID, aimed at improving physician efficiency [13] - Anticipated approval of the idiopathic indication from the NAUTILUS trial [14] Patient Flow and Market Penetration - Approximately 75,000 patients cycle through comprehensive epilepsy centers annually, indicating a modest penetration rate for RNS implants [16] - No structural barriers are identified that limit penetration; the focus is on educating clinicians and patients to facilitate adoption [17] Project CARE Initiative - The initiative has successfully broadened access to RNS beyond Level 4 centers, improving education and referral processes [20][21] Reimbursement Landscape - Positive momentum in reimbursement, with stable DRG codes and efforts to enhance physician reimbursement for monitoring patients [24][26] - Approximately 20% of the payer mix consists of traditional Medicare, with 30% from Medicare Advantage and 50% from private payers [27] NAUTILUS Trial and FDA Submission - The PMA submission for the idiopathic generalized patient population has been accepted by the FDA, indicating a productive dialogue and high-quality submission [30] - The trial demonstrated a 77% median seizure reduction rate in a highly refractory population, with a low complication rate [36] Market Opportunity - In the U.S., there are about 3.6 million people with epilepsy, with 1.2 million classified as drug-resistant. The idiopathic generalized group represents a significant subsegment of this population [41][42] - The absence of approved devices for idiopathic generalized epilepsy positions NeuroPace to capture a substantial market share upon FDA approval [43] Commercial Strategy and Drug Interaction - NeuroPace aims to work alongside pharmaceutical advancements, recognizing that a significant portion of epilepsy patients remain drug-resistant despite numerous drug approvals [51][52] - The RNS System is designed to complement drug therapies, providing a unique approach to managing epilepsy [52] Additional Important Insights - The company is proactive in preparing for market access and reimbursement processes ahead of potential FDA approval, indicating a strategic approach to commercial readiness [46][48] - The focus on patient safety and efficacy in clinical trials is emphasized as a critical factor for clinician adoption and patient trust [35][36]

Core Insights - NeuroPace, Inc. (NPCE) is focused on growth through its RNS System, a brain-responsive implant aimed at reducing seizures in adults with drug-resistant focal epilepsy, with improved sales and margins expected in 2026 due to Medicare payment changes [2][11]. Product Overview - The RNS System is a closed-loop neuromodulation implant that monitors brain activity and delivers targeted stimulation to prevent seizures, with remote programming capabilities for clinicians [4][5]. - The system includes an implantable neurostimulator, tailored leads, and a patient remote monitor, along with a physician tablet and data management system [5]. Market and Demand - The primary market for the RNS System is adult patients with drug-resistant focal epilepsy, with an estimated U.S. addressable population of around 575,000 [8]. - Demand is driven by specialized epilepsy centers, with a reimbursement framework covering the implant procedure and ongoing monitoring, impacting over 200 million covered lives as of December 2024 [9]. Revenue Model - NeuroPace generates revenue from initial and replacement sales of the RNS System, linking growth to procedure volume and the installed base [7]. - The company reported $100 million in revenue for 2025, a 25% increase from 2024, with significant growth in prescribers and implanters [11][18]. Reimbursement Changes - Medicare reimbursement updates effective January 1, 2026, will increase physician payments for RNS procedures by approximately 43% and 45% for implants and replacements, respectively [12]. - Hospital reimbursement for RNS replacement procedures will rise to $31,526 from $21,444, enhancing the economic viability for hospitals and physicians [13]. Margin and Pricing Strategy - The company has maintained disciplined pricing strategies with low to mid-single-digit increases and improved manufacturing efficiencies, leading to a gross margin of 77.4% in Q4 2025 [15][16]. - For 2026, adjusted gross margin is projected to be between 81.5% and 82.5%, supported by ongoing pricing discipline and a cleaner revenue mix [17]. Future Outlook - For 2026, total revenue guidance is set at $98 million to $100 million, with RNS growth expected at 20% to 22%, excluding contributions from DIXI and idiopathic generalized epilepsy [20]. - The company anticipates typical seasonality in growth, with a projected revenue of $21 million to $22 million for Q1 2026 [21].

Core Insights - NeuroPace, Inc. (NPCE) achieved $100 million in revenue for 2025, reflecting a 25% year-over-year growth, with a focus on the core RNS System as non-core revenue diminishes [2][10] - The company anticipates continued growth in its adult focal RNS franchise, projecting at least 20% growth for 2026, aligning with its long-term strategy [3][10] - The stock is expected to perform in line with the market, emphasizing the importance of execution, valuation, and catalysts rather than merely identifying peak performance [3] Revenue and Business Transition - The 2025 revenue growth was supported by a shift towards the core RNS business, with DIXI Medical contributing approximately 16% of revenue, which will cease after inventory sell-through by the end of 2025 [4][11] - The transition to a "pure-play" RNS model is expected to enhance profitability and operational focus, as DIXI revenue will no longer be recorded post-2025 [11][12] Operational Growth and Market Dynamics - Management highlights the expansion of growth channels beyond Level 4 comprehensive epilepsy centers, which is crucial for accelerating procedure-based adoption [5] - Medicare's reimbursement updates effective January 1, 2026, significantly increase hospital and physician payments for RNS procedures, which could enhance adoption and procedure growth [13][14] Financial Metrics and Valuation - NPCE trades at approximately 4.57x forward 12-month sales per share, above the Zacks sub-industry average of 4.11x and the Medical sector at 2.28x, but below the S&P 500 at 5.06x [6] - The company’s gross margin improved to 77.4% in Q4 2025, with RNS gross margin at 80.5%, and is expected to reach 81.5%–82.5% in 2026 [12] Near-Term Challenges - The company anticipates adjusted EBITDA losses between $9 million to $11 million in 2026, with operating expenses projected at $90 million to $92 million, primarily in the first half of the year [15] - Revenue growth is expected to be moderated in the first half of 2026, with guidance of $21 million to $22 million for Q1, potentially impacting investor sentiment [16] Investment Framework - The investment outlook suggests a focus on whether fundamentals can improve sufficiently to justify the current premium valuation compared to historical sales multiples [17]

Core Viewpoint - NeuroPace, Inc. is set to present at the Leerink 2026 Global Healthcare Conference, highlighting its focus on transforming the lives of individuals with epilepsy through innovative medical devices [1] Company Overview - NeuroPace, Inc. is based in Mountain View, California, and specializes in medical devices aimed at reducing or eliminating seizures in epilepsy patients [1] - The company’s RNS System is the first and only commercially available brain-responsive platform that provides personalized, real-time treatment at the source of seizures [1] Financial Performance - For the fourth quarter of 2025, NeuroPace reported total revenue of $26.6 million, marking a 24% increase compared to the fourth quarter of 2024 [1] - Revenue from the RNS System reached $22.4 million, reflecting a growth of 26% compared to the same period in the previous year [1]

Core Viewpoint - NeuroPace is experiencing positive market activity following its latest earnings release, which showed significant revenue growth and a reduction in net loss [1][2]. Financial Performance - In Q4 2025, NeuroPace reported revenue of $26.6 million, a 24% increase compared to Q4 2024 [2]. - The company narrowed its net loss to $2.7 million ($0.08 per share) from a loss of nearly $5.3 million in the previous year [2]. - The consensus analyst estimates were surpassed, with expected revenue of $24.4 million and a net loss per share of $0.18 [4]. Revenue Drivers - Growth was attributed to favorable Medicare reimbursement decisions and an increase in prescribers and accounts [4]. - The RNS System, an epilepsy treatment device, was the main revenue driver, with sales rising 26% to over $22 million [4]. Future Guidance - Management provided guidance for full-year 2026 revenue between $98 million and $100 million, with a non-GAAP EBITDA loss projected at $9 million to $10 million [5]. - This guidance reflects a decrease from the 2025 figures of $100 million in revenue and a $5 million EBITDA loss [5]. Market Sentiment - Despite the positive quarterly performance, the future guidance was perceived as less impressive, contributing to a muted investor reaction [6]. - The RNS System is recognized as a unique and winning product, suggesting potential for the stock [6].

Core Insights - NeuroPace reported a total revenue of $26.6 million for Q4 2025, reflecting a 24% year-over-year increase, primarily driven by RNS System sales which reached $22.4 million, up 26% from the previous year [3][7] - The company anticipates a long-term growth trajectory of at least 20% in its core RNS business within the current adult focal epilepsy indication [2] - For the full year 2025, total revenue was $100 million, a 25% increase year-over-year, with RNS System sales also up 25% [12] Financial Performance - Gross margin for Q4 was 77.4%, an improvement from 75.4% in the prior year, driven by higher-margin RNS revenue and improved manufacturing efficiency [8] - Adjusted EBITDA was positive at $0.9 million for the second consecutive quarter, with a net loss of $2.7 million, improved from $5.3 million a year earlier [9][13] - Operating expenses for Q4 were $22.3 million, up from $19.8 million a year ago, but growth remained below revenue growth, indicating operational leverage [9] Regulatory and Product Development - The FDA accepted a PMA supplement to expand RNS into idiopathic generalized epilepsy, with a 180-day review period initiated [5][20] - The AI-enabled SeizureID platform is expected to be approved in H1 2026, aimed at enhancing clinician efficiency [5][22] - NeuroPace is also advancing remote care initiatives, allowing physicians to adjust therapy settings during telehealth visits [23] Future Guidance - For 2026, the company reiterated revenue guidance of $98–100 million on a continuing-operations basis, implying underlying RNS growth of 20–22% [6][15] - The company expects adjusted operating expenses of $90–92 million and an adjusted EBITDA loss of $9–10 million for 2026 [19] - For Q1 2026, revenue is expected to be between $21 million and $22 million, with growth rates typically moderating in the first half of the year [16]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [4][18] - RNS System revenue was $22.4 million, up 26% year-over-year, contributing significantly to overall revenue growth [4][18] - Gross margin improved to 77.4%, up from 75.4% in the fourth quarter of 2024, driven by higher margin RNS revenue and manufacturing efficiencies [19] - Adjusted EBITDA was positive at $900,000 for the fourth quarter, marking a $1.9 million improvement year-over-year [22] Business Line Data and Key Metrics Changes - The core RNS business showed strong performance with a growth rate of 29% in the second half of 2025 [5] - Service revenue from data collaborations totaled approximately $890,000 in the fourth quarter [18] - Revenue from DIXI Medical was approximately $3 million, a decline of 4% compared to the fourth quarter of 2024, as the company worked to sell existing inventory before the end of the commercial partnership [18] Market Data and Key Metrics Changes - The majority of growth came from Level 4 centers, indicating increased adoption and utilization of the RNS System [6] - The company reached new highs in prescribers, accounts, and patient pipeline, reflecting broad-based momentum across the business [5] Company Strategy and Development Direction - The company is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansion [5] - Investments are being made in the commercial organization, including sales representative additions and nurse navigator resources to enhance patient navigation through the treatment process [9] - The company aims to expand its RNS therapy access through community pathways and improve referral management [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a long-term growth trajectory of at least 20% in the core RNS business [7] - The company reiterated its full-year 2026 revenue guidance of $98 million to $100 million, assuming core RNS growth of 20%-22% [8][26] - Management highlighted the potential for a transformational year in 2026, driven by ongoing market momentum and new product developments [17][34] Other Important Information - The company submitted a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE), supported by significant clinical data [10] - The SeizureID tool, designed to enhance physician workflow and improve patient outcomes, is expected to receive approval in the first half of 2026 [12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway to target key payers [38] Question: What is the impact of pricing on RNS growth in the fourth quarter? - Management noted that mid-single digit pricing increases have been consistent, contributing positively to gross margins without any significant changes in Q4 [50] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to facilitate patient flow through the referral process [60][61] Question: What is the logistics behind the SeizureID opportunity? - SeizureID will be part of the RNS System offering, aimed at improving efficiency for clinicians without additional costs for access [66]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [5][22] - RNS System revenue was $22.4 million, up 26% year-over-year, reflecting strong performance in the core business [6][22] - Gross margin improved to over 77%, up approximately 200 basis points year-over-year, driven by manufacturing efficiencies [9][24] - Adjusted EBITDA was positive at $900,000 in the fourth quarter, marking a $1.9 million improvement compared to the prior year quarter [28] Business Line Data and Key Metrics Changes - The majority of revenue growth continues to come from Level 4 centers, with RNS growth in the second half of 2025 at 29% [8] - Service revenue tied to data collaborations totaled approximately $890,000 in the fourth quarter [22] - Revenue from DIXI Medical was approximately $3 million, representing a decline of 4% compared to the fourth quarter of 2024 [22] Market Data and Key Metrics Changes - The company is focused on expanding access to RNS therapy through community pathways and referral pathways, which are contributing to growth [6][8] - The adult focal epilepsy market remains a significant opportunity, with ongoing efforts to deepen adoption and utilization [6][39] Company Strategy and Development Direction - The company aims to grow a minimum of 20% in its core RNS business with the current adult focal epilepsy indication [9] - Strategic investments are being made in the commercial organization, including sales representative additions and nurse navigator resources [11][20] - The company is pursuing an expanded indication for the RNS System in idiopathic generalized epilepsy (IGE) and has submitted a PMA supplement to the FDA [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory and the potential for a transformational 2026 [10][20] - The company is optimistic about the upcoming approval for IGE and the associated market opportunities [41][55] - Management highlighted the importance of ongoing investments in product development and clinical programs to enhance the RNS System's capabilities [42] Other Important Information - The company plans to report DIXI-related financial results as discontinued operations starting in Q1 2026 [30][31] - Full year 2026 revenue guidance is reiterated at $98 million-$100 million, excluding contributions from DIXI [32] Q&A Session Summary Question: Can you provide details on the timeline from approval to revenue collection for the generalized opportunity? - Management indicated that extending coverage in the private payer community is crucial and that preparations are already underway [46] Question: What is the magnitude of pricing impact on RNS growth in the fourth quarter? - Management noted consistent mid-single digit pricing increases annually, with no significant changes in Q4 [61] Question: What are the current dynamics regarding capacity across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being utilized to streamline patient flow [70][72] Question: Can you elaborate on the Seizure ID opportunity and its implementation? - Seizure ID will be part of the RNS System offering, aimed at improving clinician efficiency without additional costs [79]

Financial Data and Key Metrics Changes - NeuroPace reported Q4 2025 revenue of $26.6 million, a 24% year-over-year increase from $21.5 million in Q4 2024 [4][17] - RNS System revenue was $22.4 million, reflecting a 26% year-over-year growth [4][17] - Gross margin improved to 77.4%, up from 75.4% in Q4 2024, driven by higher margin RNS revenue and manufacturing efficiencies [18] - Adjusted EBITDA was positive at $900,000, marking a $1.9 million improvement year-over-year [22] - For the full year 2025, total revenue grew 25% to $100 million, with RNS System sales also increasing by 25% [24] Business Line Data and Key Metrics Changes - The core RNS business continues to show strong growth, with a 29% increase in the second half of 2025 [5] - Service revenue from data collaborations was approximately $890,000 in Q4 2025 [17] - Revenue from DIXI Medical was about $3 million, a 4% decline compared to Q4 2024, as the commercial partnership ended [17] Market Data and Key Metrics Changes - The majority of growth is coming from Level 4 centers, indicating increased adoption and utilization of the RNS System [5] - The company is expanding access to RNS therapy through community pathways and referral networks [5] Company Strategy and Development Direction - NeuroPace is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansions [5][8] - The company is investing in its commercial organization, including sales representative additions and nurse navigator resources [8] - The submission of a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE) is a key strategic move [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a minimum of 20% growth in the core RNS business for 2026 [6] - The company reiterated its 2026 revenue guidance of $98 million to $100 million, assuming 20%-22% growth in the core RNS business [7][26] - Management highlighted the importance of ongoing investments in commercial activities and product development to drive future growth [31] Other Important Information - The company achieved its second consecutive quarter of positive adjusted EBITDA and positive cash generation in Q4 2025 [7][22] - NeuroPace is advancing its product pipeline, including AI tools designed to enhance physician workflow and patient outcomes [10][12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway [38] Question: What is the impact of pricing on RNS growth in Q4? - Management noted consistent mid-single-digit pricing increases annually, with Q4 growth primarily driven by initial implants rather than pricing changes [52][54] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to streamline patient flow [62][64] Question: Will SeizureID be a subscription service for physicians? - SeizureID will be included with the use of the RNS System, aimed at improving efficiency for clinicians [68][70] Question: Any updates on the pediatric NEST collaboration? - Management confirmed ongoing work with NEST to utilize real-world evidence for focal pediatric patients, with no specific submission timeline yet [82]